Celularity Operating Margin from 2010 to 2024
| CELU Stock | USD 2.76 0.09 3.16% |
Check Celularity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celularity's main balance sheet or income statement drivers, such as Interest Expense of 2.8 M, Ebit of 17.2 M or Net Income Applicable To Common Shares of 17.1 M, as well as many indicators such as Price To Sales Ratio of 1.84, Dividend Yield of 0.0 or PTB Ratio of 1.13. Celularity financial statements analysis is a perfect complement when working with Celularity Valuation or Volatility modules.
Celularity | Operating Margin |
Latest Celularity's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Celularity over the last few years. It is Celularity's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celularity's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.84) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Celularity Operating Margin Regression Statistics
| Arithmetic Mean | (2.03) | |
| Coefficient Of Variation | (163.88) | |
| Mean Deviation | 2.77 | |
| Median | (0.000063) | |
| Standard Deviation | 3.32 | |
| Sample Variance | 11.01 | |
| Range | 8.4443 | |
| R-Value | (0.76) | |
| Mean Square Error | 4.98 | |
| R-Squared | 0.58 | |
| Significance | 0.001 | |
| Slope | (0.57) | |
| Total Sum of Squares | 154.19 |
Celularity Operating Margin History
About Celularity Financial Statements
Celularity shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Celularity investors may analyze each financial statement separately, they are all interrelated. The changes in Celularity's assets and liabilities, for example, are also reflected in the revenues and expenses on on Celularity's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. Celularity operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 225 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.